For two years I led enterprise partnership strategy behind a major AI research initiative, working the funding side of a field most people only encounter through its products. I sat across the table from technology companies and financial institutions as they decided how many millions to commit to fundamental AI research they would not control and might not directly benefit from for years. Here is what that experience — and the data since — taught me about how enterprise AI funding actually works.
AI research funding is now a corporate strategy line item, not a philanthropy line item
The scale of capital moving into AI has changed the nature of the conversation. According to the OECD’s Digital Economy Outlook, global venture capital investment in AI start-ups roughly tripled between 2015 and 2023, from USD 31 billion to USD 98 billion. Generative AI alone went from about 1% of AI venture funding in 2022 (USD 1.3 billion) to 18.2% (USD 17.8 billion) in 2023. Separately, OECD estimates put aggregate AI-related investment across the EU at EUR 257 billion in 2023, with private capital — not government funding — accounting for roughly 73% of that total.
When I was negotiating research partnerships, this shift was already underway: the largest commitments came not from philanthropic foundations but from technology and financial-services companies treating basic AI research funding as a strategic hedge — a way to stay close to research talent, shape the norms their future products would operate under, and be first in line when breakthroughs became commercially relevant.
What makes a corporate funder say yes
Across dozens of these conversations, three factors consistently separated a “yes” from a “maybe”:
1. Proximity to a named researcher or lab, not a field
Corporate partners rarely fund “AI research” in the abstract. They fund a specific lab, a specific principal investigator, or a specific research agenda they can describe in one sentence to their own board. Anonymized or diffuse research portfolios are a much harder sell than a single named initiative with a face and a thesis attached to it.
2. A seat, not just a cheque
Every successful large commitment came with some form of structured access: an advisory seat, first-look rights on publications, or a standing briefing cadence. Corporate funders were not simply buying research outcomes; they were buying an early-warning system for a fast-moving field.
3. A credible answer to “why us”
The partnerships that closed fastest were the ones where the funder’s own commercial exposure to AI mapped directly onto the research agenda — a bank funding work on AI and financial-system risk, a platform company funding work on AI and societal impact. Generic sponsorship asks, disconnected from the funder’s own risk exposure, moved much more slowly.
The five-stage lifecycle of a research partnership
Every large research commitment I negotiated moved through the same five stages, even when the participants didn’t name them that way. Understanding the stages helps you diagnose where a stalled negotiation is actually stuck.
1. Sourcing. Someone inside the funder organization needs to become a genuine advocate before a formal proposal exists. This person is rarely in the philanthropy or CSR function — they are more often in strategy, risk, or a business unit with direct commercial exposure to the research question. Skipping this stage and going straight to a written proposal is the single most common reason cold approaches fail.
2. Framing. The research agenda gets translated into the funder’s internal language — not “advancing the field,” but “what this means for our risk exposure, our product roadmap, or our talent pipeline over the next three to five years.” This stage typically takes longer than either side expects, because it requires real back-and-forth about what the funder actually needs to be able to tell their own leadership.
3. Negotiating structure. This is where the size of the commitment gets decided, but more importantly, where the access rights get defined: publication timing, advisory participation, briefing cadence, and any exclusivity or first-look provisions. Underinvesting in this stage to close faster on dollar amount alone consistently produces relationships that sour within eighteen months.
4. Governing. Once signed, the partnership needs the same governance discipline as any commercial alliance — a steering mechanism, clear reporting against the framing established in stage two, and a defined cadence for the funder’s advisory input to actually be used, not just collected.
5. Renewing or expanding. The strongest multi-year research relationships treat the original agreement as a pilot for a larger one. Building the case for expansion requires the same discipline as any partnership renewal: fresh framing, demonstrated governance, and a specific ask made before the agreement’s natural endpoint.
What this looks like from the researcher’s side
Funding negotiations are usually described from the funder’s perspective, but researchers and research institutions are making strategic choices too. The research leads who navigated corporate funding most successfully shared a few habits: they treated the funder relationship as a long-term institutional asset, not a one-time grant; they were disciplined about which findings were appropriate for early briefing versus which needed to reach peer review first, and were explicit about that boundary upfront rather than negotiating it after a dispute; and they invested time translating their own research agenda into commercial-risk language before ever approaching a corporate funder, rather than leaving that translation to the funder’s team.
The uncomfortable asymmetry: compute and capital concentration
One thing the funding conversations made clear years before it became a mainstream concern: access to compute, not just capital, increasingly determines who can do frontier AI research at all. The OECD’s most recent analysis shows the United States capturing about 75% of all AI venture capital deal value globally, with the EU, China, and the UK each in the mid-single digits. Government efforts to correct this are now substantial in their own right — the EU’s InvestAI initiative aims to mobilize over USD 200 billion, including dedicated funding for AI “gigafactories” — but the gap between where AI capital sits and where AI research talent is trained remains wide.
| Funder type | Primary motive | Typical ask in return |
|---|---|---|
| Technology platform | Talent pipeline, norm-shaping | Publication first-look, advisory seat |
| Financial institution | Risk research relevant to their sector | Briefings on systemic-risk findings |
| Government / public funder | Sovereign research capacity | National reporting, open publication |
What this means if you are the one asking for the funding
If you are building a partnership case for AI-related research, product research, or applied innovation, the enterprise funding market has matured past the point where a mission statement and a slide deck close a deal. Bring a named lead, a specific thesis, a structured access offer, and a direct answer to why this funder’s own commercial exposure makes them the right partner — not just a generous one. That is a materially different pitch than the one that worked a decade ago, and it is the one the data says is winning capital today.
Public and philanthropic funders follow a similar logic, with one key difference
Government research agencies and philanthropic foundations move through largely the same five stages as corporate funders, with one structural difference: the “framing” stage has to translate the research agenda into public-value or mission language rather than commercial-risk language, and the internal advocate is more often a program officer than a strategy executive. The negotiating-structure stage tends to be more standardized — public funders often have fixed reporting templates and less room to negotiate bespoke access rights — which can make the process faster to start but slower to customize. A funding strategy that blends public, philanthropic, and corporate sources needs a different framing document for each audience, built from the same underlying research agenda, rather than one generic pitch deck adapted on the fly.
What the trajectory implies for the next few years
Three data points from the OECD’s most recent reporting are worth watching if you are building a multi-year AI partnership or funding strategy rather than a one-off deal. First, enterprise AI adoption in the United States is still, by the OECD’s own framing, in an early growth phase — adoption rose from 5.7% to 9.2% of firms between Q4 2024 and Q2 2025, with select sectors at 25-30%, meaning most of the enterprise market has not yet made its first serious AI research or deployment commitment, and the funding relationships being built now will shape who those companies partner with once they do. Second, sovereign capital is entering the field at a scale that could change who the most attractive funding partners are: the EU’s InvestAI initiative alone targets mobilizing roughly USD 200 billion, including dedicated funding for AI infrastructure. A research group whose funding strategy is built entirely around corporate partners may be underweighting a fast-growing public-capital channel. Third, supply-side friction — tariff exposure on semiconductor imports, export controls affecting chip access — is a live variable in enterprise AI budgets in a way it was not three years ago, and funding negotiations increasingly need to account for the possibility that a funder’s own AI infrastructure costs could shift materially mid-agreement.
Template: the funding pitch one-pager
Mirroring the renewal-brief discipline from partnership management generally, the research funding pitches that moved fastest through a corporate funder’s internal approval process shared a one-page format: a single sentence naming the lead researcher and the specific question being studied; one paragraph translating that question into the funder’s own risk or opportunity language; the specific commitment being requested, broken into a dollar figure and a set of access rights, listed separately rather than bundled; a short paragraph on why this funder specifically, tied to their own commercial exposure; and a named internal contact on the funder’s side who has already agreed to sponsor the proposal internally. Proposals missing that last element — a genuine internal sponsor, not just a submission portal — rarely moved past the framing stage no matter how strong the research case was on its own merits.
Frequently asked questions
How much of an enterprise AI research budget typically goes to funding external partnerships versus internal research? This varies enormously by sector and company size, and the OECD data does not break this out cleanly at the enterprise level. What I observed directly is that companies newer to funding external AI research tend to start with smaller, single-lab commitments to build internal confidence in the model before scaling to larger, multi-year partnerships.
Is the compute concentration problem something an individual partnership can address? Not on its own, but a partnership’s structure can partially mitigate it — negotiating access to the funder’s own compute infrastructure as part of the deal, rather than only cash, is increasingly a meaningful ask for research groups outside the small set of institutions with abundant compute of their own.
What is the biggest sign a research funding negotiation is about to stall? When the conversation stays at the “framing” stage for more than two or three meetings without moving toward specific structural terms. That is usually a sign the internal advocate has not yet secured real buy-in from their own leadership, and no amount of additional research detail from your side will resolve that until it’s addressed directly.
Does the size of the initial commitment predict whether a research partnership will renew? Less than you’d expect. The strongest predictor I saw across these negotiations was governance discipline in the first year, not the size of the first cheque. A modest first-year commitment, well-governed and clearly reported against, renewed and expanded far more reliably than a large first commitment that lacked a working steering mechanism.
Takeaways
- Enterprise AI funding is now driven by strategic hedging, not philanthropy — frame the ask accordingly.
- Fund a name and a thesis, not a field.
- Offer structured access (advisory seats, first-look rights) alongside the ask for capital.
- Anchor the pitch in the funder’s own commercial exposure to the research question.
- Watch compute concentration, not just capital concentration — it increasingly determines who can even compete for this funding.